Compare Cytokinetics Inc (CYTK) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Kimberly Clark Corp — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while Kimberly Clark Corp trades at $97.47 (market cap $32.51B). The key difference: Kimberly Clark Corp is far larger — about 3.8× Cytokinetics Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Kimberly Clark Corp for 93 Days on average.
| CYTK | KMB | |
|---|---|---|
Market Cap | $8.62B | $32.51B |
Volume | 2,594,626 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $121.44 |
52-Week Low | $54.76 | $93.05 |
Typical Hold Time | 19 Days | 93 Days |
Enterprise Value | $8.72B | $38.07B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Kimberly-Clark (KMB) trades at $98.02, up 1.6% on the day, showing modest recovery from recent weakness. The stock faces bearish technical signals with support at $96 and resistance at $98. Fundamentally, the company maintains strong profitability with 11.79% net margins and consistent dividend payments, though revenue declined to $16.45B in 2025. Recent executive transitions and the pending Kenvue acquisition create both uncertainty and strategic opportunity.
KMB offers a compelling dividend yield above 5% with 54 consecutive years of increases, but faces execution risks from the Kenvue integration. Analyst consensus targets $117.25 (19% upside) with mixed sentiment (32% buy, 58% hold). The stock presents value for income investors but requires careful monitoring of acquisition progress and cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
